The FDA has approved Ofev (nintedanib; Boehringer Ingelheim) for the treatment of patients with chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype.
Individuals with HIV were more likely to have interstitial lung abnormalities and findings suspicious for the presence of interstitial lung disease than individuals without HIV.
Use of thrombomodulin alfa for the treatment of acute exacerbation of idiopathic pulmonary fibrosis is not recommended, according to phase 3 clinical trial results.
Patients with idiopathic pulmonary fibrosis are faced with a heavy economic burden, with mean annual costs for admission and inpatient care totaling more than $10,000 per patient.
Higher adiponectin levels are associated with lower high attenuation areas, a computed tomography-based measure of subclinical interstitial lung disease.
ARDS was underrecognized in the study population across all body mass indexesBMIs, but this underrecognition did not explain why patients with class 3 obesity were more likely to meet ARDS criteria but not receive low tidal volume ventilation.
Metformin was effective in reducing pulmonary fibrosis in human IPF fibroblasts and when used in combination with low-dose nintedanib, demonstrated a synergistic, antifibrotic effect.
